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Abstract 
Background: Prophylactic vaccination against human papillomavirus (HPV) is available for the 
prevention of cervical, vaginal, vulvar, penile, and oral cancers. Physician recommendation is an 
important predictor of adolescent patient vaccination, and future HPV vaccination programs 
should address physician concerns to encourage uptake worldwide. Few data are currently 
available on differences in providers’ recommendations for and attitudes towards HPV 
vaccination across different geographical settings. 
Methods: A total of 151 adolescent vaccine providers were interviewed from five 
geographically representative countries (Argentina, Malaysia, South Africa, South Korea, and 
Spain) from October 2013 and April 2014.  
Results: Most physicians (83%) believed the vaccine protects against cervical cancer and genital 
warts (37%). Negative perspectives included high cost [(50%; range 26%:  South Africa-77%: 
Korea)]; and doubts concerning vaccine safety and efficacy [(19%: range 7%: South Africa-33%: 
Spain)]. Overall, over half of physicians (54%) would recommend HPV vaccination always or 
most of the time [(range: 13%: Malaysia-77%: Spain)]. Most physicians (74%) stated they were 
comfortable recommending the vaccine, although Korea was an outlier (33%). Free, low-cost, or 
publicly available vaccines [(39%: range 26%: South Africa-57%: Korea)] and additional data on 
vaccine safety and efficacy [(62%: range 3%: Malaysia-80%: Spain)] were the most commonly 
cited facilitators of vaccine recommendation.  
Discussion: Countries varied greatly in the proportion of providers recommending HPV vaccine 
always or most of the time, which may be due to cultural differences or national vaccine 
availability in some regions. Physicians’ most commonly cited concerns about vaccination 
included safety and efficacy, likely due to its recent introduction, or not yet being routinely 
available in some countries.  
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Introduction 
 
Problem Statement 
 
HPV vaccines are used to prevent cervical cancer, which today is the second most 
common cancer worldwide. Approximately 85% of cases occur in developing countries (266,000 
deaths per year and 528,000 new cases in 2012), with most of these cases occurring in sub-
Saharan Africa, South Asia, and Latin America.1, 2 For example, in South Africa, cervical cancer 
is the third leading cause of death among women, with an incidence rate of 30 per 100,000 per 
year.3 
        Almost all (99%) of cases of cervical cancer are linked to human papillomavirus (HPV) 
infection, a sexually transmitted infection affecting over 290 million women worldwide.4 The 
first HPV vaccine was approved in 2006, and was hailed as a major breakthrough in preventing 
cervical cancer.5 The recommended age for HPV vaccination is usually between nine and fifteen 
years old, before sexual activity has started, although women can receive the vaccine through 26 
years of age in the United States.6 
In spite of being available, however, a host of countries are at different stages in their 
coverage process. In Argentina, HPV vaccination has become part of the National Immunization 
program under the Ministry of Health recommendations.7 In contrast, in Malaysia, the vaccine 
has been recommended for use, though it is not mandatory in school-based programs along with 
other vaccines such as diphtheria.8 In South Africa, the vaccine has been licensed, but it is only 
available to the private sector given its cost.9 
Dosing can also pose a challenge. The HPV vaccine requires three doses (usually at 0, 1 
or 2, and 6 months), which can make it difficult to complete the entire schedule of doses. 
However, newer, two-dose schedules are currently being studied 10—and in some cases have been 
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found to be the most cost-effective option with the assumption that protection would last for at 
least 20 years.11 
Compounded, these factors have led to relatively low vaccination rates worldwide. In 
fact, in one study in Argentina carried out between 2009 and 2010, only six out of 1200 women 
surveyed on HPV vaccine acceptability had completed the three-dose schedule, and none within 
the range of 9-15 years old had been vaccinated at all.12 
Vaccine acceptability is an important predictor of vaccine uptake in these countries. While 
qualitative data exists on mothers’ acceptance of HPV vaccines, as they are often the ones 
making decisions about their children’s healthcare,13 there is also a growing body of literature 
available from the provider point of view.14 Providers occupy a unique position in the health 
systems framework and can reveal facilitators and barriers to HPV vaccine provision. However, 
quantitative global data on provider vaccination practices is scarce. 
 In this research project, I will use existing quantitative data from provider interviews in 
five countries (Argentina, Malaysia, South Africa, South Korea, and Spain) to identify factors 
associated with physician recommendations of the HPV vaccine based on a variety of factors, 
including: 
 country 
 type of provider 
 years of clinical practice 
 place of vaccine provision  
 type of vaccine provision (i.e. public or private) 
 racial/ethnic characteristics of patients 
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 average age of adolescent girls seen within recommended HPV vaccination age (9-14 
years of age) 
 knowledge of HPV vaccine recommendations (i.e. whether vaccination is recommended 
within the country of study, recommended targeted age group, and knowledge of 
vaccination dosing). 
Research Question: 
What factors influence providers’ HPV vaccination recommendation practices across five 
countries (Argentina, Malaysia, South Africa, South Korea, and Spain)? 
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Background 
Prophylactic vaccination against human papillomavirus (HPV) is currently available to 
prevent cervical, vaginal and vulvar cancers in women, penile cancer in men, and oral cancers in 
both genders.15 Today, three HPV vaccines are available: bivalent, quadrivalent, and nonavalent.  
The bivalent vaccine targets antigens for two HPV strains, 16 and 18 (associated with 70% of 
cervical cancers), while the quadrivalent vaccine contains antigens for four HPV types: 16, 18, 6 
and 11 for  protection against genital warts.16 Recently, a nonavalent vaccine has been approved 
in the United States against nine types of HPV infection (newly including HPV types 31, 33, 45, 
52, and 58) to provide protection of ~90% of cervical cancers.17 
HPV vaccination coverage among female adolescents (the target group) differs notably 
across countries.18-21 Methods to ensure wide population-based coverage are needed to ensure the 
maximum benefits from HPV vaccination. Patients often rely on physician judgment when 
making decisions about their children’s health, 22 and physician recommendation has been 
characterized as one of the most important factors leading to a decision to get vaccinated against 
HPV.23-25 Provider recommendation can not only help explain differences in vaccine coverage, 
but can also identify issues to be addressed for provider training. 
Due to the lack of data currently available and the important position healthcare providers 
occupy within healthcare delivery, it is important to determine physician opinions about and 
recommendation practices on HPV vaccination. This is especially important to understand 
differences in providers’ recommendation practices across diverse geographical regions, with 
notable differences in health services and cultural acceptability for adolescent vaccination. 
Although separate data sets exist,26, 27 none have consolidated these analyses into one global 
aggregate based solely on the physician perspective of HPV vaccination. 
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Thus, we present here data on healthcare providers’ HPV vaccine recommendation 
practices in Argentina, Korea, Malaysia, South Africa, and Spain in order to present for the first 
time such a wide variety of global aggregate data. Furthering our understanding of physician 
perceptions and practices can help public health leaders reduce such disparities through helping 
them target public health interventions to ensure higher vaccine coverage.  
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Methodology 
Data source 
To identify physicians’ practices and recommendations for HPV vaccination, individual 
structured face-to-face interviews were conducted with 151 adolescent vaccine providers in five 
geographically representative countries between October 2013 and April 2014. Approximately 
thirty providers each in country were chosen by non-probability convenience sampling: 
Argentina (n=30), Malaysia (n=30), South Africa (n=31), South Korea (n=30), and Spain (n=30).  
Providers were considered eligible if they had ever administered any vaccine to adolescents, and 
if they were authorized by national vaccination standards to administer vaccination.  Specific 
recruitment methods included outreach to study staff contacts, snowball sampling, review of 
databases from national professional organizations, national health insurance 
review/assessments, websites, and lists from external consultants.  Interviewers collected 
eligibility and consent from interested providers. The study was approved by the UNC Office of 
Human Ethics, along with Institutional Review Boards of each of the five collaborating 
countries. 
A survey (codebook in appendix) consisted of 66 questions in two versions: one version 
for providers who had ever administered HPV vaccines and another version for providers who 
administer adolescent vaccines but who had never administered HPV vaccination. Interview 
questionnaires were adapted from previous instruments and issues related to HPV vaccination 
documented in the literature, including physician perspectives of the benefits and disadvantages 
of administering the vaccine.27-30  
Eligibility, consent and interview survey documents were translated from English into 
local languages when necessary. Country study staff entered de-identified data into English 
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language Epidata forms, translating data into English when necessary. Interview data were 
double entered and coded quantitatively using STATA (StataCorp, Texas). 
Data analysis 
We conducted simple frequency tabulations with univariate analyses for specific data 
collected on i) provider socio-demographic characteristics, ii) provider opinions about the 
benefits and negative aspects of HPV vaccination, iii) provider comfort and discomfort in 
recommending HPV vaccination, iv) facilitating factors of HPV vaccine recommendation, v) the 
frequency at which providers recommended HPV vaccination and vi) reasons for not always 
recommending HPV vaccination.31, 32   
Ethical Considerations 
This study was considered exempt from the Institutional Review Board of the University 
of North Carolina at Chapel Hill. 
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Results 
Physician HPV vaccine recommendation frequency 
When asked, 67 (44%) physicians would always recommend HPV vaccination. However, 
this was variable across the five countries as only 17% of Korean providers would always 
recommend the vaccine, compared to 13% of physicians in Malaysia (Table 1). Approximately 
ten percent of providers (15) would recommend the vaccine most of the time (none in Spain and 
17% in Argentina and Korea). In contrast, 48 (32%) providers would only recommend it 
sometimes or hardly ever, ranging from 7% in Spain to 63% in Malaysia. In addition, 19 (13%) 
physicians would either never recommend the vaccine or only when a patient asked for it, with 
none in Argentina and 26% in South Africa. Finally, one (1%) South African provider stated that 
the vaccine had not yet been implemented at the time of study. 
Physician opinions about HPV vaccine 
Physicians had a range of opinions about the HPV vaccine. The vast majority of 
physicians (125, 83%) believed the vaccine protects against cervical cancer [(range: 97%: South 
Korea to 68%: South Africa)] (Table 2). In addition, 56 (37%) of physicians believed the HPV 
vaccine would provide protection against genital warts, ranging from 10% in Korea to 83% in 
Spain. Out of 151 participants, 23 (15%) believed its long-lasting immunity was a major asset, 
with 7% of physicians in Spain and 20% of physicians in Korea and South Africa citing this as a 
positive aspect. Only 13 (9%) physicians stated the vaccine was safe and had few adverse events 
or could reduce the need for routine cervical cancer screening, with none in Korea and Malaysia 
stating this and 19% of South African physicians citing this. Eight (5%) providers responded 
they did not like anything about the HPV vaccine or had never heard of it, ranging from none in 
Kundu 12 
 
Korea and Malaysia to 13% of physicians in Spain. Finally, one provider (1%) in South Africa 
stated patients could receive other vaccinations at the same visit as a positive aspect of the 
vaccine. 
In contrast, cost was a major negative aspect for 75 (50%) physicians, ranging from 26% 
in South Africa to 77% in Korea. An additional 28 (19%) providers stated the vaccine was 
unsafe or could cause adverse events (7% in South Africa and 33% in Spain), whereas 24 (16%) 
physicians recognized the pain of the shot (10% in South Africa and 20% in Argentina and 
Malaysia). Approximately 23 (15%) physicians either didn’t know, had never heard of the 
vaccine, or liked everything about the vaccine, with 3% in Korea and 20% in Argentina and 
Spain. Physicians (19, 13%) also cited implementation problems (i.e. too many doses), ranging 
from 7% in Malaysia and Spain to 20% in South Africa. In addition, 14 providers (9%) believed 
vaccination would not reduce the need for routine cervical cancer screening, with none citing this 
in Korea and Malaysia and 20% citing this in Argentina and Spain. A few (12, 8%) of providers 
cited negative perceptions of the vaccine along with a lack of parental support as a negative 
aspect of the vaccine, ranging from 3% in Malaysia to 13% in Argentina. Out of the 150, ten 
(7%) of providers stated there was not enough evidence (none in Malaysia, South Africa, and 
Spain and 27% in Argentina). Approximately nine providers (6%) believed the vaccine did not 
lead to long-lasting immunity, with none in Malaysia and South Africa believing this and 17% in 
Spain believing this. Four providers (3%) in Argentina and South Africa also cited the vaccine 
not being approved for all ages as a negative aspect. Only three (2%) physicians stated that the 
likelihood of girls having sex would increase if vaccinated, all in South Africa.  
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Physician reasons for not always recommending vaccine 
One of the most prominent reasons for not recommending the vaccine was its cost; 26 
(31%) of physicians believed vaccine cost was too high or insurance coverage was difficult to 
determine (6% in South Africa and 48% in Korea) (Table 3). Another 20 (19%) providers noted 
a lack of time or difficulty discussing sexual issues as reasons for not always recommending the 
vaccine, ranging from none in Argentina and Spain to 48% of providers in Malaysia. Next most 
common, 17 providers (20%) said there was not enough evidence or a lack of information in 
recommending the vaccine, or that it was not effective, safe, or useful, or other. Out of the 151 
providers, twelve (14%) stated the vaccine was not yet implemented or available or the vaccine 
was recently introduced, refused, or didn’t know, with none in Argentina and Korea and 56% in 
South Africa. Finally, four physicians total (5%) in Argentina (1), Korea (2), and Malaysia (1) 
stated that they did not always recommend the vaccine because too few patients wanted the 
vaccine or it was too hard to recommend or the up-front costs of ordering, stocking, and storing 
HPV vaccine was too high, reimbursement was often late or inadequate, or refrigerator space 
was lacking (Argentina, Malaysia, and South Africa). 
Physician comfort in recommending vaccine and reasons for discomfort 
Overall, most (112, 74%) physicians stated they were very comfortable or a little 
comfortable recommending the vaccine, with Korea being the outlier as only 33% of Korean 
physicians felt comfortable recommending the vaccine (Table 4). Only 36 (24%) physicians 
were a little uncomfortable or very uncomfortable recommending the vaccine, ranging from 10% 
in South Africa to 67% in Korea. Finally, two (1%) South African physicians refused to answer 
or did not know. 
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Out of the 36 physicians who were uncomfortable recommending the vaccine, 20 (56%) 
of physicians cited high costs as a reason for discomfort, ranging from none in South Africa to 
80% in Korea. In addition, 11 (31%) providers cited concerns about vaccine safety and side 
effects as a reason for discomfort, with none in Malaysia and 75% in Spain. Only a quarter of the 
36 physicians (9 in Korea and Malaysia) stated they were uncomfortable discussing sexual health 
or sexually transmitted infections, and another quarter from all countries except Malaysia cited 
unproven efficacy and not enough long term data. Next, eight (22%) of providers in all countries 
except South Africa said nothing, did not know, or other as a reason for discomfort. Finally, 
another six (17%) providers in Argentina, Malaysia, and South Africa stated the vaccine was not 
publicly available, general uncertainty, or concerns about the vaccine were factors in their 
discomfort. 
Factors that would facilitate recommendation 
There were a multitude of factors that physicians stated would help them to recommend 
HPV vaccination for patients. Physicians stated a free, low-cost, or publicly available vaccine 
would be an effective facilitator [(range: 26% in South Africa to 57% in Korea)] (Table 5). 
Approximately one third of providers (52, 34%) also wanted more data on vaccine safety, 
ranging from 10% of physicians in Malaysia to 80% of physicians in Spain. Additionally, 43 
(28%) of providers wanted more data on vaccine efficacy, ranging from 3% of providers in 
Malaysia to 80% of providers in Spain. Another twenty-five (17%) of providers noted a school-
based program as an effective facilitator, with none in Spain and 40% of providers in Korea. 
Next, 22 (15%) of physicians cited supportive parents and family of the vaccine, along with 
greater demand for the vaccine and meetings and campaigns targeting parents as factors that 
would facilitate recommendation (none in Spain and 30% in Argentina). Approximately 20 
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(13%) of physicians would like more general information, along with educational campaigns, 
promotions, and advertisements, ranging from none in Argentina to 26% in South Africa. A total 
of 11 (7%) of physicians in Argentina, Malaysia, and South Africa said nothing, refused, or 
didn’t know. Only 9 (6%) providers in Korea and Malaysia cited no need for booster or fewer 
doses as an effective facilitator. Finally, 6 (4%) physicians in Argentina, Korea, and Spain 
provided other factors that would facilitate recommendation. 
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Discussion 
Overall, countries varied greatly in HPV vaccine recommendation. The majority of 
adolescent providers would recommend the vaccine always or most of the time in Argentina, 
Spain, and South Africa in contrast to under a third who would recommend the vaccine always 
or most of the time in Malaysia and South Korea. This suggests strong cultural differences in 
vaccine recommendation across the countries of study. As physicians also cited other 
implementation reasons for not recommending the vaccine, national vaccine availability in some 
regions may be a cause for low vaccine recommendation frequency as well. In terms of positive 
aspects, physicians strongly believed in the vaccine’s protection against cervical cancer and 
genital warts, relatively constant among the five countries. 
 However, cost also played a large role in vaccine recommendation. In total, half of the 
151 physicians across the five countries stated cost as a negative aspect, and 31% of physicians 
stated that cost was a factor for not always recommending the vaccine. Physicians also doubted 
vaccine safety and efficacy, which may be because the vaccine is so new and was implemented 
only recently. Roughly three-quarters of physicians stated concerns about vaccine safety, 
efficacy, and other uncertainty as reasons for discomfort in recommending the vaccine. In 
addition, many physicians said more data on vaccine safety and long term efficacy would act as a 
facilitator to recommending the vaccine. Malaysia was an outlier here, as only one Malaysian 
physician said more data on long term efficacy would be a facilitator. 
These findings are consistent with previous studies. For one, there is wide variation in 
vaccine acceptability across different parts of the world36. Costs have also been cited as a major 
influence in recommending vaccines in a South African systematic review.37 Another study of 
194 Malaysian physicians also found that cost was a significant barrier to vaccine 
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recommendation. Finally, a study of 174 Argentinian gynecologists found that physicians’ own 
doubts about vaccine safety and the vaccine’s high cost negatively influenced physician vaccine 
recommendation.38  
While this study was unique as a global consolidation of data, sample sizes may have 
been too small in each country. Because data are considered as a global aggregate, cultures and 
beliefs regarding the vaccination may be ignored in favor of more quantitative data. 
Additionally, a sample of approximately 30 providers per nation may not be representative of all 
adolescent vaccine providers within that nation. The sample was not purposive. Many providers 
were also chosen through snowball sampling, and so personal social networks to study 
investigators may have played a role in vaccine recommendation frequencies and practices of 
interviewed providers.  
In addition, data were collected between October of 2013 and April 2014, and new HPV 
vaccine developments have taken place within that time (i.e. development of the nonavalent 
vaccine).  
Advantages to this study include a global aggregation of valuable data. Although 
previous studies have compared regions or data in the United States and United Kingdom, none 
to date have looked at such a wide variety of nations spanning three continents. In addition, 
provider recommendation is the most important factor in vaccine uptake, and so these findings 
have important implications in public health interventions to increase vaccine uptake. 
In short, this study contained rich and variable data for each of the five countries on 
physician HPV vaccine recommendation. Moving forward, these can be used to inform national 
vaccine programs to encourage vaccine uptake and decrease rates of cervical cancer worldwide. 
Kundu 18 
 
Acknowledgments  
Jennifer Smith1, Silvina Ramos2, Karen Morgan3, Chan Joo Kim4, Karen Richter5, M.P. Tuser6 
Authors Affiliations:  
1 Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, 
Chapel Hill, Chapel Hill, North Carolina, USA 
2Centro de Estudios de Estado y Sociedad, Buenos Aires, Argentina 
3Perdana University – Royal College of Surgeons in Ireland School of Medicine, Malaysia  
4Department of Obstetrics and Gynecology, The Catholic University of Korea College of Medicine, St. 
Paul’s Hospital, Seoul, Korea 
5Department of Medical Virology, University of Pretoria, National Health Laboratory Service, South 
Africa 
6Unit of Infections and Cancer, Cancer Epidemiology Research Programme, Institut Català d'Oncologia, 
Spain 
 
 
 
Kundu 19 
 
References 
1) World Health Organization. Preparing for the introduction of HPV vaccines: policy and 
programme guidance for countries. World Health Press, Geneva, Switzerland, 2006, p.1-22. 
2) Francis, S. A., Nelson, J., Liverpool, J., Soogun, S., Mofammere, N., & Thorpe, R. J. (2010). 
Examining attitudes and knowledge about HPV and cervical cancer risk among female clinic 
attendees in Johannesburg, South Africa. Vaccine, 28(50), 8026-8032. 
3) Francis, S. A., Nelson, J., Liverpool, J., Soogun, S., Mofammere, N., & Thorpe, R. J. (2010). 
Examining attitudes and knowledge about HPV and cervical cancer risk among female clinic 
attendees in Johannesburg, South Africa. Vaccine, 28(50), 8026-8032. 
4) World Health Organization. Preparing for the introduction of HPV vaccines: policy and 
programme guidance for countries. World Health Press, Geneva, Switzerland, 2006, p.1-22. 
5) Sharma, R. (2012). HPV vaccine: a breakthrough in prevention of cervical cancer. Apollo 
Medicine, 9(2), 87-90. 
6) Brisson, M., Van de Velde, N., & Boily, M. C. (2009). Economic evaluation of human 
papillomavirus vaccination in developed countries. Public Health Genomics, 12(5-6), 343-351. 
7) Arrossi, S., Maceira, V., Paolino, M., & Sankaranarayanan, R. (2012). Acceptability and uptake 
of HPV vaccine in Argentina before its inclusion in the immunization program: a population-
based survey. Vaccine, 30(14), 2467-2474. 
8) Wong, L. P. (2009). Physicians’ experiences with HPV vaccine delivery: evidence from 
developing country with multiethnic populations. Vaccine,27(10), 1622-1627. 
9) Harries, J., Moodley, J., Barone, M. A., Mall, S., & Sinanovic, E. (2009). Preparing for HPV 
vaccination in South Africa: key challenges and opinions.Vaccine, 27(1), 38-44. 
10) Jit, M., Brisson, M., Laprise, J. F., & Choi, Y. H. (2015). Comparison of two dose and three dose 
human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission 
model. BMJ, 350, g7584. 
11) Jit, M., Brisson, M., Laprise, J. F., & Choi, Y. H. (2015). Comparison of two dose and three dose 
human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission 
model. BMJ, 350, g7584. 
12) Arrossi, S., Maceira, V., Paolino, M., & Sankaranarayanan, R. (2012). Acceptability and uptake 
of HPV vaccine in Argentina before its inclusion in the immunization program: a population-
based survey. Vaccine, 30(14), 2467-2474. 
13) 13) Olshen, E., Woods, E. R., Austin, S. B., Luskin, M., & Bauchner, H. (2005). Parental 
acceptance of the human papillomavirus vaccine. Journal of Adolescent Health, 37(3), 248-251. 
14) 14) Brewer, N. T., & Fazekas, K. I. (2007). Predictors of HPV vaccine acceptability: a theory-
informed, systematic review. Preventive medicine,45(2), 107-114. 
15) World Health Organization. Preparing for the introduction of HPV vaccines: policy and 
programme guidance for countries. World Health Press, Geneva, Switzerland, 2006, p.1-22. 
16) World Health Organization. Preparing for the introduction of HPV vaccines: policy and 
programme guidance for countries. World Health Press, Geneva, Switzerland, 2006, p.1-22. 
17) U.S. Food and Drug Administration. (2014, December 10).FDA approves Gardasil 9 for 
prevention of certain cancers caused by five additional types of HPV. U.S. Department of Health 
and Human Services. Retrieved from 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426485.htm. 
18) Francis, S. A., Nelson, J., Liverpool, J., Soogun, S., Mofammere, N., & Thorpe, R. J. (2010). 
Examining attitudes and knowledge about HPV and cervical cancer risk among female clinic 
attendees in Johannesburg, South Africa. Vaccine, 28(50), 8026-8032. 
19) Arrossi, S., Maceira, V., Paolino, M., & Sankaranarayanan, R. (2012). Acceptability and uptake 
of HPV vaccine in Argentina before its inclusion in the immunization program: a population-
based survey. Vaccine, 30(14), 2467-2474. 
Kundu 20 
 
20) Wong, L. P. (2009). Physicians’ experiences with HPV vaccine delivery: evidence from 
developing country with multiethnic populations. Vaccine,27(10), 1622-1627. 
21) Olshen, E., Woods, E. R., Austin, S. B., Luskin, M., & Bauchner, H. (2005). Parental acceptance 
of the human papillomavirus vaccine. Journal of Adolescent Health, 37(3), 248-251. 
22) Hofstetter, A. M., & Rosenthal, S. L. (2014). Factors impacting HPV vaccination: lessons for 
health care professionals. Expert review of vaccines,13(8), 1013-1026. 
23) Chow, S. N., Soon, R., Park, J. S., Pancharoen, C., Qiao, Y. L., Basu, P., & Ngan, H. Y. S. 
(2010). Knowledge, attitudes, and communication around human papillomavirus (HPV) 
vaccination amongst urban Asian mothers and physicians. Vaccine, 28(22), 3809-3817. 
24) Wong, L. P. (2009). Physicians’ experiences with HPV vaccine delivery: evidence from 
developing country with multiethnic populations. Vaccine,27(10), 1622-1627. 
25) Jit, M., Brisson, M., Laprise, J. F., & Choi, Y. H. (2015). Comparison of two dose and three dose 
human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission 
model. BMJ, 350, g7584. 
26) Wong, L. P. (2009). Physicians’ experiences with HPV vaccine delivery: evidence from 
developing country with multiethnic populations. Vaccine,27(10), 1622-1627. 
27) Arrossi, S., Maceira, V., Paolino, M., & Sankaranarayanan, R. (2012). Acceptability and uptake 
of HPV vaccine in Argentina before its inclusion in the immunization program: a population-
based survey. Vaccine, 30(14), 2467-2474. 
28) Wong, L. P. (2009). Physicians’ experiences with HPV vaccine delivery: evidence from 
developing country with multiethnic populations. Vaccine,27(10), 1622-1627. 
29) Chow, S. N., Soon, R., Park, J. S., Pancharoen, C., Qiao, Y. L., Basu, P., & Ngan, H. Y. S. 
(2010). Knowledge, attitudes, and communication around human papillomavirus (HPV) 
vaccination amongst urban Asian mothers and physicians. Vaccine, 28(22), 3809-3817. 
30) Francis, S. A., Nelson, J., Liverpool, J., Soogun, S., Mofammere, N., & Thorpe, R. J. (2010). 
Examining attitudes and knowledge about HPV and cervical cancer risk among female clinic 
attendees in Johannesburg, South Africa. Vaccine, 28(50), 8026-8032. 
31) Brewer, N. T., & Fazekas, K. I. (2007). Predictors of HPV vaccine acceptability: a theory-
informed, systematic review. Preventive medicine,45(2), 107-114. 
32) Rosenthal, S. L., Weiss, T. W., Zimet, G. D., Ma, L., Good, M. B., & Vichnin, M. D. (2011). 
Predictors of HPV vaccine uptake among women aged 19–26: importance of a physician's 
recommendation. Vaccine, 29(5), 890-895. 
33) Wong, L. P. (2009). Preventing cervical cancer through human papillomavirus vaccination: 
perspective from focus groups. Journal of Lower Genital Tract Disease, 13(2), 85-93. 
34) Rosenthal, S. L., Weiss, T. W., Zimet, G. D., Ma, L., Good, M. B., & Vichnin, M. D. (2011). 
Predictors of HPV vaccine uptake among women aged 19–26: importance of a physician's 
recommendation. Vaccine, 29(5), 890-895. 
35) Szumilas, M. (2010). Explaining odds ratios. Journal of the Canadian Academy of Child and 
Adolescent Psychiatry, 19(3), 227. 
36) Sharma, R. (2012). HPV vaccine: a breakthrough in prevention of cervical cancer. Apollo 
Medicine, 9(2), 87-90. 
37) Perlman, S., Wamai, R. G., Bain, P. A., Welty, T., Welty, E., & Ogembo, J. G. (2014). 
Knowledge and awareness of HPV vaccine and acceptability to vaccinate in sub-Saharan Africa: 
a systematic review. PloS one, 9(3), e90912. 
38) Wong, L. P. (2009). Physicians’ experiences with HPV vaccine delivery: evidence from 
developing country with multiethnic populations. Vaccine,27(10), 1622-1627. 
